Below are citations to some relevant scientific publications regarding the use of molecular iodine for reproductive health and the differences associated with the ingestion of the various forms of iodine.

Human Clinical Observations

Vishnyakova VV and Mura’yeva NI. On the treatment of dyshormonal hyperplasia on mammary glands. Vestin. Sakad. Med. Mauk. S.S.S.R. 1966;21:26-31.

Ghent W.R. and Eskin B.A., Iodine replacement in fibrocystic disease of the breast, Can J Surg, 1993;36:453-60.

Eskin BA and Ghent RA. Treatment of iodine deficiency diseases; U.S. Patent Nos. 5,589,198; 5,389,385; 4,816,255; 5,171,582; and 5,250,304.

The Effect of Supraphysiologic Levels of Iodine on Patients with Cyclic Mastalgia, The Breast Journal, Vol 10(4): pp 328-336 July 2004.

Iodine Deficiency Animal Model for Fibrocystic Breast Tissue

Brown-Grant B. The iodide concentrating mechanism of the mammary gland. J. Physiol. 1957;135:644-654.

Eskin BA, Bartusda DG, Dunn MR, Jacob G, and Dratman MB. Mammary gland dysplasia in iodine deficiency. JAMA 1967;200(8):115-9.

Aquino TI, Eskin BA. Rat breast structure in altered iodine metabolism. Arch. Path., 1972;94:280-5.

Eskin BA, Parker JA, Bassett JG, George DL. Human breast uptake of radioactive iodine. Obstet. Gynec. 1974:44(3):398-402.

Eskin BA, Shuman R, Krouse T, Merion JA. Rat mammary gland atypia produced by iodine blockade with perchlorate. Cancer Research, 1975;35:2332-9.

Strum JM. Site of iodination in rat mammary gland. Anat. Rec. 1978;192:235-44.

Strum JM. Effect of iodide-deficiency on rat mammary gland. Virchows Arch. B Cell Path. 1979;30:209-220.

Eskin BA, Grotokowsik CE, Connolly CP, Ghent WR. Different Tissue Responses for Iodine and Iodide in Rat Thyroid and Mammary Glands. Biol. Trace Elem. Res. 1995;49:9-19.

Epidemiological and Anecdotal Observations

Stadel BV. Dietary iodine and risk of breast, endometrial and ovarian cancer. Lancet 1976;1:890-1.
Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Lancet, 1896;2:104-7.

Clur A. DI-Iodothyronine as part of the oestradiol and catechol oestrogen receptor. Medical Hypotheses, 1988;27:303-11.

Breast Cancer and Fibrocystic Breast Disease

Dupont W, Page DL Risk factors for breast cancer in women with proliferative breast disease. New Engl. J. Med. 1985,312(3):146-51.

Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am. J. Epid. 1988,128:467-77.

London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992,267(7):941-4.

Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993,71(4):1258-65.

Fabian CJ, Zalles C, Kamel S, McKittrick R, Moore WP, Zeiger S, Simon C, Kimler B, Cramer A, Garcia F, Jewell W. Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. J. Cell. Biochem. 1993,17G:153-60.

Fabian CJ, Kamel S, Zalles C, Kimler BF. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J. Cell. Biochem. 1996,25S:112-22.

Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF. Breast cytology and biomarkers obtained by random fine needle aspiration. J. Cell. Biochem. 1997,28/29:101-10.

Fabian CJ, Kimler BF, Elledge RM, Grizzle WE, Beenken, SW, Ward JH. Models for early chemoprevention trials in breast cancer. Hematology/Oncology Clin. North Am. 1998,12(5):993-1017.

Friedenreich, C.; Bryant, H.; Alexander, F.; Hugh, J.; Danyluk, J.; Page, D. Risk factors for benign proliferative breast disease. Int J Epidemiol 2000,29(4):637-44./

Daniels GH and Haber DA. Will radioiodine be useful in the treatment of breast cancer?. Nature Med. 2000,6(8)859-60.

Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao HQ, Deng HF, Amenta PS, Finberg S, Pestell RG, Carrasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nature Med. 2000,6(8)871-8.

Kimler BF, Fabian CJ, Wallace DD. Breast cancer chemoprevention trials using the fine-needle aspiration model. J. Cell. Biochem. 2000,34:7-12.

Oral Iodine Toxicity

Vagneakis AG, Downs P, Braverman LE, Burger A, Ingbar SH. Control of thyroid hormone secretion in normal subjects receiving iodides. J. Clin. Invest. 1973;37:443-9.

Paul T, Meyeres B, Witorsch RJ, Pino S, Chipkin S, Ingbar SH, Braverman LE. The effect of small increases in dietary iodine on thyroid function in euthyroid subjects. Metab. 1988;37(2):121-4.
Pennington JAT. A review of iodine toxicity reports. J. Am. Diet. Assoc. 1990;90:1571-81.

Thrall KD. Formation of Organic By-Products Following Consumption of Iodine Disinfected Drinking Water. Ph.D. Dissertation, December 1990.

Thrall KD. Bull RJ. Differences in the distribution of iodine and iodide in the Sprague-Dawley rat. Fund. App. Tox. 1990;15:75-81.

Sherer TT, Thrall KD, Bull RJ. Comparison of toxicity induced by iodine and iodide in male and female rats. J. Tox. Env. Health 1991; 32:89-101.

Thrall KD, Bull RJ, Sauer RL. Distribution of iodine into blood components of the Sprague-Dawley rat differs with the chemical form administered. J. Tox. Env. Hellth 1992;37:443-9.

Lemar HJ, Georgitis WH, McDermott MT. Thryoid adaptioation to chronic tetraglycine hydroperiodide water purification tablet use. J. Clin. Endo. Metab. 1995;80:220-3.